These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37212896)

  • 1. Prognostic predictors for recurrence following curative resection in grade I/II pancreatic neuroendocrine tumours.
    Chopde A; Gupta A; Chaudhari V; Parghane R; Basu S; Ostwal V; Ramaswamy A; Puranik A; Shrikhande SV; Bhandare MS
    Langenbecks Arch Surg; 2023 May; 408(1):204. PubMed ID: 37212896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
    Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
    J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
    Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
    Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-free survival after pancreatectomy for pancreatic neuroendocrine tumors: A 17-year single-center experience of 223 patients.
    Mukkala AN; Ray S; Bevacqua D; McGilvray I; Sapisochin G; Moulton CA; Gallinger S; Cleary SP; Shwaartz C; Wei AC; Reichman TW
    J Gastrointest Surg; 2024 Sep; 28(9):1485-1492. PubMed ID: 38906319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
    Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
    World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence and outcomes of non-functional pancreatic neuroendocrine tumours post-resection: an Australian retrospective, multicentre cohort study.
    Lim S; Chong L; Peeroo S; Onasanya O; He E; Banting S; Croagh D
    ANZ J Surg; 2023 Jan; 93(1-2):160-165. PubMed ID: 36562118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors of long-term outcome in surgically resectable pancreatic neuroendocrine tumors: A 12-year experience from a single center.
    Zhou B; Duan J; Yan S; Zhou J; Zheng S
    Oncol Lett; 2017 Mar; 13(3):1157-1164. PubMed ID: 28454228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis analysis of patients with pancreatic neuroendocrine tumors after surgical resection and the application of enucleation.
    Chen J; Yang Y; Liu Y; Kan H
    World J Surg Oncol; 2021 Jan; 19(1):11. PubMed ID: 33436017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
    Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and outcomes of patients for non-functioning pancreatic neuroendocrine tumours: a multi-institutional analysis.
    Du B; Wang X; Zhang W; Tan Q; Wei Y; Shao Z
    ANZ J Surg; 2022 Apr; 92(4):787-793. PubMed ID: 34723424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimally Invasive vs Open Pancreatectomy for Pancreatic Neuroendocrine Tumors: Multi-Institutional 10-Year Experience of 1,023 Patients.
    Zheng J; Pulvirenti A; Javed AA; Michelakos T; Paniccia A; Lee KK; Ferrone CR; Wei AC; He J; Zureikat AH;
    J Am Coll Surg; 2022 Aug; 235(2):315-330. PubMed ID: 35839409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Outcomes of Parenchyma-sparing and Oncologic Resections in Patients With Nonfunctional Pancreatic Neuroendocrine Tumors <3 cm in a Large Multicenter Cohort.
    Bolm L; Nebbia M; Wei AC; Zureikat AH; Fernández-Del Castillo C; Zheng J; Pulvirenti A; Javed AA; Sekigami Y; Petruch N; Qadan M; Lillemoe KD; He J; Ferrone CR;
    Ann Surg; 2022 Sep; 276(3):522-531. PubMed ID: 35758433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of recurrence after the resection of pancreatic neuroendocrine tumors.
    Chouliaras K; Newman NA; Shukla M; Swett KR; Levine EA; Sham J; Mann GN; Shen P
    J Surg Oncol; 2018 Sep; 118(3):416-421. PubMed ID: 30259518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience.
    Cienfuegos JA; Salguero J; Núñez-Córdoba JM; Ruiz-Canela M; Benito A; Ocaña S; Zozaya G; Martí-Cruchaga P; Pardo F; Hernández-Lizoáin JL; Rotellar F
    Surg Endosc; 2017 Oct; 31(10):3847-3857. PubMed ID: 28127714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrovascular venous invasion of pancreatic neuroendocrine tumours: impact on surgical outcomes and survival.
    Addeo P; d'Alessandro A; Averous G; Imperiale A; Faitot F; Goichot B; Bachellier P
    HPB (Oxford); 2019 Jun; 21(6):653-661. PubMed ID: 30522946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis.
    Broadbent R; Wheatley R; Stajer S; Jacobs T; Lamarca A; Hubner RA; Valle JW; Amir E; McNamara MG
    Cancer Treat Rev; 2021 Dec; 101():102299. PubMed ID: 34662810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Outcomes Following Surgery for Locally Advanced Pancreatic Neuroendocrine Tumors.
    Titan AL; Norton JA; Fisher AT; Foster DS; Harris EJ; Worhunsky DJ; Worth PJ; Dua MM; Visser BC; Poultsides GA; Longaker MT; Jensen RT
    JAMA Netw Open; 2020 Nov; 3(11):e2024318. PubMed ID: 33146734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.
    Zhao CL; Dabiri B; Hanna I; Lee L; Xiaofei Z; Hossein-Zadeh Z; Cao W; Allendorf J; Rodriguez AP; Weng K; Turunbedu S; Boyd A; Gupta M
    Ann Diagn Pathol; 2023 Aug; 65():152149. PubMed ID: 37119647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major postoperative complications after pancreatic resection for P-NETS are not associated to earlier recurrence.
    Valente R; Lykoudis P; Tamburrino D; Inama M; Passas I; Toumpanakis C; Luong TV; Davidson B; Imber C; Malagò M; Rahman SH; Shankar A; Sharma D; Caplin M; Fusai G
    Eur J Surg Oncol; 2017 Nov; 43(11):2119-2128. PubMed ID: 28821361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.